Clinical Trial Update: Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 study evaluating the combination of bortezomib with tacrolimus and methotrexate to prevent graft-versus-host disease after mismatched a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Prograf (Tacrolimus)
• Velcade (bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Hematologic Malignancies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-07-25